Synmosa Biopharma Total Liabilities
Synmosa Biopharma total liabilities. Based on the latest financial reports, Synmosa Biopharma (4114) has total liabilities worth NT$3.89 Billion TWD (≈ $122.43 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4114 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Synmosa Biopharma (2015–2025)
Total liabilities of Synmosa Biopharma from 2015 to 2025. This chart illustrates how Synmosa Biopharma's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Synmosa Biopharma's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Synmosa Biopharma Competitors by Total Liabilities
The table below lists competitors of Synmosa Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
China | CN¥987.01 Million |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
China | CN¥195.24 Million |
|
ENTERA BIO IS-0000769
F:5DT
|
Germany | €12.21 Million |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
China | CN¥1.01 Billion |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
China | CN¥381.30 Million |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
Sweden | Skr8.78 Billion |
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
China | CN¥1.50 Billion |
|
BlueLinx Holdings Inc
NYSE:BXC
|
USA | $982.54 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Synmosa Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Synmosa Biopharma asset portfolio.
Liquidity & Leverage Metrics
Synmosa Biopharma Total Liabilities Ratios Explained
Synmosa Biopharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synmosa Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synmosa Biopharma (2015–2025)
The table below shows the annual total liabilities of Synmosa Biopharma from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$3.89 Billion ≈ $122.43 Million |
-0.49% |
| 2024-12-31 | NT$3.91 Billion ≈ $123.04 Million |
+7.65% |
| 2023-12-31 | NT$3.63 Billion ≈ $114.29 Million |
-20.34% |
| 2022-12-31 | NT$4.55 Billion ≈ $143.47 Million |
+7.87% |
| 2021-12-31 | NT$4.22 Billion ≈ $133.00 Million |
-4.55% |
| 2020-12-31 | NT$4.42 Billion ≈ $139.34 Million |
+12.91% |
| 2019-12-31 | NT$3.92 Billion ≈ $123.41 Million |
+28.03% |
| 2018-12-31 | NT$3.06 Billion ≈ $96.39 Million |
-13.54% |
| 2017-12-31 | NT$3.54 Billion ≈ $111.48 Million |
+45.22% |
| 2016-12-31 | NT$2.44 Billion ≈ $76.77 Million |
+54.36% |
| 2015-12-31 | NT$1.58 Billion ≈ $49.73 Million |
-- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more